Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IMRX
stocks logo

IMRX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.312
-46.26%
--
--
-0.350
-16.67%
--
--
-0.370
-7.5%
Estimates Revision
The market is revising No Change the revenue expectations for Immuneering Corporation (IMRX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 21.42%.
EPS Estimates for FY2025
Revise Downward
down Image
-13.84%
In Past 3 Month
Stock Price
Go Up
up Image
+21.42%
In Past 3 Month
Wall Street analysts forecast IMRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMRX is 17.60 USD with a low forecast of 11.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast IMRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMRX is 17.60 USD with a low forecast of 11.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.690
sliders
Low
11.00
Averages
17.60
High
30.00
Current: 6.690
sliders
Low
11.00
Averages
17.60
High
30.00
Leerink
Outperform
initiated
$15
2025-10-31
Reason
Leerink
Price Target
$15
2025-10-31
initiated
Outperform
Reason
Leerink initiated coverage of Immuneering with an Outperform rating and $15 price target. The firm notes lead asset atebimetinib is an allosteric MEK inhibitor that has shown compelling Phase 2 activity in combination with chemotherapy in first-line pancreatic ductal adenocarcinoma, a tumor type in which over 90% of patients are driven by aberrant, constitutive MAPK signaling. Leerink thinks DCI, which departs from conventional, continuous kinase inhibition and uses high dose, pulsatile blockade, introduces mechanistic risk. However, it sees significant upside if efficacy and tolerability are confirmed in the pivotal trial by allowing a more tolerable approach to MEK inhibition. The firm views atebi as a blockbuster+ agent in PDAC with $2.4B peak revenues, representing $14/share in its model.
Mizuho
NULL -> Outperform
maintain
$10 -> $12
2025-10-29
Reason
Mizuho
Price Target
$10 -> $12
2025-10-29
maintain
NULL -> Outperform
Reason
Mizuho raised the firm's price target on Immuneering to $12 from $10 and keeps an Outperform rating on the shares.
Oppenheimer
Jay Olson
Outperform
maintain
$21 -> $30
2025-09-25
Reason
Oppenheimer
Jay Olson
Price Target
$21 -> $30
2025-09-25
maintain
Outperform
Reason
Oppenheimer analyst Jay Olson raised the firm's price target on Immuneering to $30 from $21 and keeps an Outperform rating on the shares after the company surprised with an earlier-than-expected update on atebimetinib in 1L PDAC. The firm says that "the sooner the better when data are this strong," exceeding expectations that it had recently laid out. Encouragingly, the 9-month overall survival rate, a key focus of the update, achieved 86%, well above Oppenheimer's 75% expectation and clearly separated from historical GnP benchmarks. The favorable OS outcome was further supported by an impressive 53% PFS rate at 9 months, which altogether reinforces the efficacy contribution of atebimetinib on top of mGnP. Moreover, atebimetinib+mGnP continued to demonstrate a favorable tolerability profile, the firm adds.
Mizuho
NULL
to
Outperform
maintain
$8 -> $10
2025-06-19
Reason
Mizuho
Price Target
$8 -> $10
2025-06-19
maintain
NULL
to
Outperform
Reason
Needham
Ami Fadia
Strong Buy
Reiterates
$12
2025-04-10
Reason
Needham
Ami Fadia
Price Target
$12
2025-04-10
Reiterates
Strong Buy
Reason
Chardan Capital
Geulah Livshits
Strong Buy
Maintains
$13
2025-03-24
Reason
Chardan Capital
Geulah Livshits
Price Target
$13
2025-03-24
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Immuneering Corp (IMRX.O) is -4.71, compared to its 5-year average forward P/E of -3.93. For a more detailed relative valuation and DCF analysis to assess Immuneering Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.93
Current PE
-4.71
Overvalued PE
-0.34
Undervalued PE
-7.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.73
Undervalued EV/EBITDA
-5.73

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
293.71
Current PS
0.00
Overvalued PS
1100.69
Undervalued PS
-513.26
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

IMRX News & Events

Events Timeline

(ET)
2025-11-12
16:28:28
Immuneering anticipates sufficient cash to sustain operations through 2029.
select
2025-11-12
16:28:11
Immuneering Announces Q3 Earnings Per Share of 38 Cents, Below Consensus Estimate of 39 Cents
select
2025-09-25 (ET)
2025-09-25
05:32:04
Immuneering Prices 18.96M Share Spot Secondary at $9.23
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.0
11-27NASDAQ.COM
Immuneering (IMRX) Receives Upgrade to Buy: Implications for the Stock

  • Zacks Rank Upgrade: Immuneering Corporation (IMRX) has received a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates, indicating a positive outlook for its stock price.

  • Earnings Estimate Revisions: The Zacks Consensus Estimate for Immuneering has increased by 13% over the past three months, reflecting analysts' growing confidence in the company's earnings potential.

  • Investment Strategy: The Zacks rating system, which categorizes stocks based on earnings estimate revisions, has a strong track record, with top-rated stocks historically generating significant returns.

  • AI Investment Opportunities: The article highlights the potential for significant wealth creation in the next phase of AI development, suggesting that early investors in emerging companies could see substantial gains.

[object Object]
Preview
9.0
11-19Globenewswire
Targeted Cancer Treatments Accelerate as Precision Medicine Market Exceeds $106 Billion

  • Precision Oncology Market Growth: The precision oncology sector is rapidly evolving, with the market reaching $106.21 billion in 2025 and projected to grow to $158.9 billion by 2029, driven by advancements in biomarker-driven therapies and immunotherapy modalities.

  • Oncolytics Biotech's Pivotal Trial: Oncolytics Biotech has received FDA alignment for its Phase 3 study of pelareorep in pancreatic cancer, aiming to provide the first immunotherapy option for this indication, with promising preliminary data showing significant response rates.

  • ALX Oncology's Clinical Success: ALX Oncology reported a 65% objective response rate for its candidate evorpacept in treating high CD47-expressing HER2-positive gastric cancer, significantly outperforming standard therapies and guiding future clinical strategies.

  • Innovations from Other Biotech Firms: Companies like Erasca, Immuneering, and Prelude Therapeutics are advancing their respective therapies and programs, with notable achievements in patent protections and promising clinical trial results, indicating a strong pipeline in the oncology sector.

[object Object]
Preview
4.0
11-13Benzinga
Chardan Capital Reaffirms Buy Rating on Immuneering with $20 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from shared intelligence.

  • Market Winning Tools: Benzinga Pro is designed to help traders win in the markets every day with accurate stock market intelligence.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Immuneering Corp (IMRX) stock price today?

The current price of IMRX is 6.69 USD — it has decreased -0.74 % in the last trading day.

arrow icon

What is Immuneering Corp (IMRX)'s business?

Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.

arrow icon

What is the price predicton of IMRX Stock?

Wall Street analysts forecast IMRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMRX is 17.60 USD with a low forecast of 11.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Immuneering Corp (IMRX)'s revenue for the last quarter?

Immuneering Corp revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Immuneering Corp (IMRX)'s earnings per share (EPS) for the last quarter?

Immuneering Corp. EPS for the last quarter amounts to -0.38 USD, decreased -22.45 % YoY.

arrow icon

What changes have occurred in the market's expectations for Immuneering Corp (IMRX)'s fundamentals?

The market is revising No Change the revenue expectations for Immuneering Corporation (IMRX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 21.42%.
arrow icon

How many employees does Immuneering Corp (IMRX). have?

Immuneering Corp (IMRX) has 66 emplpoyees as of December 05 2025.

arrow icon

What is Immuneering Corp (IMRX) market cap?

Today IMRX has the market capitalization of 431.97M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free